Efficacy of a Diabetes Onset Prevention App System Utilizing Continuous Glucose Monitoring and Artificial Intelligence in Individuals at High Risk for Type 2 Diabetes

Efficacy of a Diabetes Onset Prevention App System Utilizing Continuous Glucose Monitoring and Artificial Intelligence in Individuals at High Risk for Type 2 Diabetes - Evaluation of an A- and Continuous Glucose Monitoring Based App to Support the Prevention of Type 2 Diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000060579

Enrollment

660

Registered

2026-02-13

Start date

2026-02-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prediabetes

Interventions

Intervention using a continuous glucose monitoring function + AI-powered disease prevention application system Standard diabetes prevention guidance

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Individuals with HbA1c < 6.5 percent and fasting blood glucose < 126 mg/dL and random blood glucose < 200 mg/dL 2. Individuals meeting condition 1 HbA1c >= 6.0 percent and fasting blood glucose >= 103 mg/dL or condition 2 HbA1c >= 6.2 percent or condition 3 fasting blood glucose >= 112 mg/dL 3. Individuals aged 20 years or older and 70 years or younger at the time of consent acquisition 4. Individuals with a BMI >= 25 kg/m2 and < 40 kg/m2 5.Individuals capable of using the smartphone application employed in the research 6. Individuals who have received an explanation of the research content and have provided consent to participate in the study

Exclusion criteria

Exclusion criteria: 1.Individuals currently receiving treatment for diabetes 2.Individuals deemed inappropriate for participation by the attending physician

Design outcomes

Primary

Measure	Time frame
The incidence of diabetes mellitus before and after the intervention will be compared between the intervention group and the control group.	—

Countries

Japan

Contacts

Public ContactMasaru Kitazawa

Graduate School of Medical and Dental Sciences, Niigata University Department of Haematology, Endocrinology and Metabolism

m-kitazawa.med@niigata-u.ac.jp0253689026

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026